In consultation: Guidance and quality standards
Showing 1 to 4 of 4
| Title | Consultation | Type | Consultation end date |
|---|---|---|---|
| Ripretinib for treating advanced gastrointestinal stromal tumours after 3 or more treatments (review of TA881) [ID6496] | Draft guidance | Technology appraisal guidance | |
| Sodium zirconium cyclosilicate for treating hyperkalaemia (partial review of TA599) [ID6439] | Draft guidance | Technology appraisal guidance | |
| Sebetralstat for treating acute attacks of hereditary angioedema in people aged 12 and over [ID6284] | Draft guidance | Technology appraisal guidance | |
| Palopegteriparatide for treating chronic hypoparathyroidism [ID6380] | Draft guidance | Technology appraisal guidance |